Paxil®
Paroxetine
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$200+ (brand Paxil)
With Insurance
$5–20
How It Works
Paroxetine blocks serotonin reuptake like all SSRIs — but it also blocks several other receptor systems simultaneously, which is the source of its unique and problematic side effect profile. It is the "dirtiest" SSRI.
Why the side effects happen
Paroxetine's weight gain, dry mouth, constipation, sedation, and sexual dysfunction all have specific receptor-level explanations. The anticholinergic burden (M1 blockade) also explains why paroxetine causes the worst discontinuation syndrome — it affects more receptor systems simultaneously. The 21-hour half-life is the shortest of any SSRI, so the brain "crashes" quickly when a dose is missed.
When Will I Feel It?
Similar onset to other SSRIs: 2–4 weeks for initial response, 6–8 weeks for full effect. However, side effects like weight gain and sexual dysfunction often emerge earlier than the antidepressant benefit.
Sedation, nausea, weight increase may begin immediately. Many patients find it calming — this sedation is from H1 blockade, not the antidepressant.
Antidepressant effect begins. Sexual dysfunction often apparent by now. Weight gain starting.
Full antidepressant and anxiolytic effect. Weight gain ongoing with continued use.
Weight gain continues (average 5–10 lbs at 12 months). Discontinuation becomes harder with longer use.
Adherence Note
Because paroxetine has a 21-hour half-life, missing even one dose can cause "brain zap" discontinuation symptoms. This is not dangerous but is profoundly uncomfortable — and is often misinterpreted as the underlying illness returning, which drives patients to keep taking it.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Sexual dysfunction
70%Highest rate of any SSRI. Includes delayed orgasm, reduced libido, anorgasmia. Discuss dose reduction, drug holiday, or switching to a different antidepressant.
Weight gain
25%Highest weight gain of any SSRI — average 5–10 lbs over 12 months. Exercise and dietary vigilance are essential.
Drowsiness / fatigue
24%Take at bedtime to leverage sedation; usually improves over weeks.
Dry mouth
18%Stay hydrated; sugar-free gum helps.
Constipation
14%Anticholinergic effect — highest of any SSRI. Increase fiber and water intake.
Nausea (initial)
26%Take with food; usually resolves in 1–2 weeks.
Sweating
22%Particularly nocturnal sweating. Dose timing adjustment may help.
Serious Adverse Effects
- • Suicidality — FDA black box warning for under-24 population; Study 329 reanalysis showed underreported suicidal events in adolescent trials
- • Severe discontinuation syndrome — shortest half-life of any SSRI; abrupt stopping causes intense brain zaps, dizziness, flu-like symptoms, crying spells
- • PPHN (persistent pulmonary hypertension of newborn) — among highest risk of any SSRI in pregnancy; Category D
- • Neonatal adaptation syndrome — withdrawal symptoms in newborn if taken in third trimester
- • Serotonin syndrome — especially if combined with other serotonergic agents
- • Hyponatremia — especially in elderly; dangerous and underdiagnosed
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Suicidality — FDA black box warning for under-24 population; Study 329 reanalysis showed underreported suicidal events in adolescent trials
- Severe discontinuation syndrome — shortest half-life of any SSRI; abrupt stopping causes intense brain zaps, dizziness, flu-like symptoms, crying spells
- PPHN (persistent pulmonary hypertension of newborn) — among highest risk of any SSRI in pregnancy; Category D
- Neonatal adaptation syndrome — withdrawal symptoms in newborn if taken in third trimester
- Electric-shock/"brain zap" sensations in head — expected but should trigger slower taper
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Highest cardiac malformation risk among SSRIs. Associated with PPHN (life-threatening newborn pulmonary hypertension). Among the riskiest SSRIs in pregnancy — consider alternatives if antidepressant is needed.
Low amounts in breast milk. Monitor infant for sedation, feeding difficulties, and irritability.
A low-dose version of paroxetine (Brisdelle, 7.5mg) is FDA-approved specifically for menopausal hot flashes — the only non-hormonal drug with this approval. However, it does not address the full spectrum of menopause symptoms the way hormone therapy does. Full-dose Paxil for menopause-related mood changes carries serious discontinuation risks and is among the hardest SSRIs to stop.
Not FDA approved for any pediatric indication. Study 329 was conducted in adolescents with fraudulent results. Black box warning for suicidality under 18. Off-label use is strongly discouraged given the research fraud history.
Beers Criteria: highest-risk SSRI in elderly. Strong anticholinergic effects increase fall risk, confusion, urinary retention. Sertraline or escitalopram preferred if antidepressant needed.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Depression & Anxiety Without the Discontinuation Risk
CBT shows comparable efficacy to SSRIs for depression and anxiety — and when combined, outperforms either alone. It has no discontinuation syndrome.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Cognitive Behavioral Therapy (CBT)
Strong12–20 sessions with a trained therapist
Meta-analyses show CBT is equivalent to antidepressants for mild-to-moderate depression; superior long-term because skills persist after therapy ends
Aerobic exercise (150 min/week)
StrongBrisk walking, running, cycling
Multiple RCTs: 30–47% reduction in depressive symptoms; comparable to antidepressants in mild-moderate depression; no discontinuation syndrome
Omega-3 (EPA-dominant, 1–2g/day)
ModerateEPA >60% of formula
RCT meta-analysis: significant antidepressant effect, especially EPA-dominant formulas. Useful as adjunct or monotherapy in mild-to-moderate depression.
Behavioral Activation (BA)
StrongStructured activity scheduling
RCTs show behavioral activation is equally effective to CBT and antidepressants for moderate depression, with fewer resources required
Mediterranean diet
ModerateAnti-inflammatory dietary pattern
SMILES trial 2017: dietary intervention reduced depression scores significantly vs. social support control — diet independently affects mood
Key Studies
How It Compares
Paroxetine is the highest-risk SSRI for weight gain, sexual dysfunction, anticholinergic effects, and discontinuation syndrome. In independent head-to-head comparisons, it consistently performs worse on tolerability than sertraline or escitalopram.
Strengths
- Effective across multiple anxiety disorders
- Sedating properties useful in severe anxiety/PTSD
- Premenstrual dysphoric disorder (PMDD) — evidence base
Weaknesses
- Highest weight gain of any SSRI
- Worst discontinuation syndrome of any SSRI
- Potent CYP2D6 inhibitor — dangerous interactions with tamoxifen
- Highest anticholinergic burden → highest dementia risk in elderly (Beers Criteria)
- Category D in pregnancy (cardiac malformations, PPHN)
- Study 329 fraud legacy
Clinically Preferred Alternatives
Global Prescribing & Pricing
United States
$15–40 (generic)/mo
Widely prescribed despite fraud history; no national restriction on prescribing in those under 25
FDA black box requires warnings but does not restrict prescribing. No mandatory psychotherapy prerequisite at federal level.
Typically covered
United Kingdom
~$5–10/mo
NICE guidelines: antidepressants should not be first-line for mild depression; therapy preferred
NICE strongly recommends CBT before SSRIs for mild-to-moderate depression. Paroxetine specifically flagged for discontinuation severity in guidance documents.
NHS covered with therapy-first recommendation
Germany
~$8–18/mo
Psychotherapy-first culture; lower SSRI prescribing than US
German S3 guidelines recommend psychological interventions as first-line. Paroxetine's discontinuation profile is explicitly noted in prescribing guidance.
GKV covered
Japan
~$10–25/mo
Lower antidepressant use overall; cultural stigma and different diagnostic thresholds
Approved in Japan; prescribing patterns reflect cultural differences in depression diagnosis and treatment approach.
Covered with restrictions
The UK's NICE guidelines and Germany's S3 guidelines both recommend psychotherapy as first-line treatment before any antidepressant for mild-to-moderate depression — the most common indication for Paxil. The US has no equivalent national standard, resulting in significantly higher antidepressant prescribing rates than peer nations.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
Study 329 is one of the most documented cases of research fraud in psychiatric history. The 2001 paper in JAACAP — largely ghost-written by a medical communications company hired by SmithKline Beecham — claimed Paxil was "generally well tolerated and effective" for adolescent depression. A 2015 independent reanalysis of the original raw data (RIAT project, BMJ) found paroxetine was no more effective than placebo, and that serious adverse events including suicidality were deliberately misclassified. GlaxoSmithKline paid $3 billion in 2012 in the largest healthcare fraud settlement in US history — which included charges related to pediatric Paxil marketing.
Declared Conflicts of Interest
The lead author of Study 329 (Dr. Martin Keller) had undisclosed financial ties to SmithKline Beecham. The paper was written by Sally K. Laden of Scientific Therapeutics Information — a medical communications firm — before any academic author contributed. Email evidence recovered in litigation revealed the intent to downplay suicidality data.
Key Efficacy Results
Study 329 original: "effective and well tolerated." Study 329 RIAT reanalysis: no significant efficacy vs. placebo; increased suicidality and other serious adverse events. The original paper has never been formally retracted despite multiple calls from researchers.
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Paroxetine. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Paroxetine in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| Study 329 RIAT Reanalysis (BMJ 2015) | PMID:26248392 | |
| GSK $3B DOJ Settlement (2012) | DOJ-GSK-2012 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Paroxetine has the shortest half-life of any SSRI (21 hours vs. fluoxetine's 4–6 days). This makes abrupt stopping — or even missing a dose — cause intense discontinuation symptoms: severe "brain zaps," dizziness, electric-shock sensations in the head, extreme irritability, flu-like symptoms, and vivid nightmares. Many patients are mistakenly told these are withdrawal symptoms "that won't happen with antidepressants." They will, and they can be severe.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Published protocols describe switching to fluoxetine before reducing — its long half-life makes the stopping process significantly smoother
- ·If staying on paroxetine: published schedules describe reducing by no more than 5–10mg every 2–4 weeks
- ·Liquid paroxetine is used for micro-tapering at the end of the process — available by prescription and documented in emerging research
- ·Research supports the "10% of current dose" approach: reducing by 10% of the CURRENT dose, not the original dose
- ·Published literature documents the stopping process taking 3–12 months for long-term users
- ·Some evidence supports hydroxyzine or beta-blockers for managing acute symptoms during the stopping process
Warning Symptoms — Contact Your Doctor If You Experience:
- Electric-shock/"brain zap" sensations in head — expected but should trigger slower taper
- Suicidal thoughts emerging or worsening during discontinuation
- Severe dizziness or inability to function
- Extremely vivid nightmares or sleep disruption
- Extreme emotional lability or crying spells
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Are you aware of the Study 329 research fraud and the $3 billion GSK settlement — and how does that affect your confidence in Paxil's safety data?
- 2.Given paroxetine has the most severe discontinuation syndrome of any SSRI, what is your plan to help me get off this medication if I need to?
- 3.I take tamoxifen — is paroxetine safe given it blocks tamoxifen's active metabolite?
- 4.Has therapy been offered as a first-line option before this prescription?
- 5.What is your monitoring plan for weight, sexual function, and my discontinuation strategy?
Lab Tests to Request
- PHQ-9 or MADRS depression scale at baseline and monthly
- Body weight baseline and quarterly
- Sexual function screen (ASEX)
- Sodium level if elderly (hyponatremia risk)
- Review all medications for CYP2D6 interactions (especially tamoxifen)
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Paxil®
- What is Paxil® used for?
- Paxil® (Paroxetine) is a SSRI manufactured by GlaxoSmithKline / Generic. FDA-approved indications include: Major depressive disorder; Panic disorder; Social anxiety disorder; PTSD; OCD; Generalized anxiety disorder; Premenstrual dysphoric disorder (PMDD).
- What are the common side effects of Paxil®?
- Common side effects of Paxil® include: Sexual dysfunction (70%); Weight gain (25%); Drowsiness / fatigue (24%); Dry mouth (18%); Constipation (14%).
- How much does Paxil® cost?
- Paxil® list price is approximately $200+ (brand Paxil). With insurance it typically costs $5–20; without insurance approximately $15–40.
- Who funded the clinical trials for Paxil®?
- Study 329 is one of the most documented cases of research fraud in psychiatric history. The 2001 paper in JAACAP — largely ghost-written by a medical communications company hired by SmithKline Beecham — claimed Paxil was "generally well tolerated and effective" for adolescent depression. A 2015 independent reanalysis of the original raw data (RIAT project, BMJ) found paroxetine was no more effective than placebo, and that serious adverse events including suicidality were deliberately misclassified. GlaxoSmithKline paid $3 billion in 2012 in the largest healthcare fraud settlement in US history — which included charges related to pediatric Paxil marketing.
- How strong is the clinical evidence for Paxil®?
- Key studies: Study 329 (2001, retracted), RIAT reanalysis (BMJ 2015), SmithKline Beecham Adolescent Depression trials. Study 329 original: "effective and well tolerated." Study 329 RIAT reanalysis: no significant efficacy vs. placebo; increased suicidality and other serious adverse events. The original paper has never been formally retracted despite multiple calls from researchers. Potential conflicts of interest: The lead author of Study 329 (Dr. Martin Keller) had undisclosed financial ties to SmithKline Beecham. The paper was written by Sally K. Laden of Scientific Therapeutics Information — a medical commun.
- Are there non-drug alternatives to Paxil®?
- CBT shows comparable efficacy to SSRIs for depression and anxiety — and when combined, outperforms either alone. It has no discontinuation syndrome. See the Alternatives tab for full details.
Get notified when we update Paxil®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.